Quick Search 
Drug News & Perspectives
Register or sign in

  
 
  
Drug News Perspect 2007, 20(8): 495
ISSN 0214-0934
Copyright 2007 Clarivate Analytics
CCC: 0214-0934
 



LOOKING AHEAD

While the benefits of mTOR inhibition in the treatment of cancer are obvious, regulation of mTOR activity may also be beneficial for the treatment of a number of other diseases.

The mTOR Pathway as a Potential Target for the Development of Therapies Against Neurological Disease

by Daniel Zemke, Seema Azhar and Arshad Majid



Summary

The mammalian target of rapamycin (mTOR) is a protein tyrosine kinase that regulates cell proliferation and survival via its effects on transcription, translation and autophagy. The activity of mTOR is controlled by a number of nutrient and energy sensing pathways, inhibiting cell proliferation under conditions of deprivation. In addition, mTOR has been associated with the inhibition of apoptosis and the clearance of toxic protein aggregates. Many neurodegenerative diseases are characterized by neuronal death via apoptosis, and it is possible that modulation of mTOR activity may offer some protection against their effects. In particular, diseases involving oxygen and nutrient deprivation, such as stroke, or diseases characterized by aggregate formation, such as Alzheimer's and Huntington's disease, could gain substantial benefit by either inhibiting or enhancing mTOR activity. In addition, inhibition of mTOR in cancerous tissue decreases cell proliferation and increases apoptosis, and is an effective therapy for brain tumors. In this article, the effects of mTOR and their potential usefulness for the treatment of neurological disease are examined © 2007 Prous Science. All rights reserved.



Full Text: HTMLPDF 
 
  



© Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy